Deutsche Welle: Dengue: a closer look at a spreading fever
“With Mexico, the Philippines, and now Brazil giving the green light to Dengvaxia, the first antidote to dengue fever ever released globally, the bandwagon has begun to roll. Regulators in all three countries authorized use of the vaccine [in December], providing a nice Christmas present for French pharmaceuticals giant Sanofi, which said Dengvaxia could bring in revenues in excess of $1 billion (920,000 euros)…” (Borrud, 12/30).

International Business Times: Dengue Vaccine From Sanofi Approved In Brazil After Cases Triple In A Year
“…Dengue, once native to only nine countries, is now endemic in over 100 countries and infects as many as 400 million people a year. The deadliest of its four strains kills 22,000 people a year, mainly children, according to World Health Organization data. Dengvaxia is effective against all four strains of the virus, Sanofi said…” (Goenka, 12/29).

Smithsonian SmartNews: Introducing the First Dengue Fever Vaccine
“…Sanofi’s vaccine isn’t the only one in development against the illness, but it was the first to gain approval. The vaccine itself uses a live but weakened form of yellow fever virus — which is related to dengue — that carries genetic modifications to help it mimic some of dengue’s proteins…” (Fessenden, 12/31).

Syracuse.com: Meet the ‘Infectious Disease Cowboys’ who are hunting down dengue fever in Syracuse
“…Dr. Timothy Endy, chief of the Infectious Disease Division at Upstate Medical University, … and Dr. Mark Polhemus are at the center of an effort to build a new defense against dengue. They are working with a $12 million federal grant from the Army. They are ironing out how to infect human volunteers with mild versions of the four strains of dengue fever…” (Eisenstadt, 1/3).